Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-cystic Fibrosis Bronchiectasis
Latest Information Update: 31 Oct 2024
At a glance
- Drugs HSK 31858 (Primary)
- Indications Bronchiectasis
- Focus Registrational; Therapeutic Use
- Sponsors Haisco Pharmaceutical Group
- 31 Oct 2024 New trial record